CA3141694A1 - Selective histamine h3 receptor antagonists for treating autism spectrum disorder - Google Patents
Selective histamine h3 receptor antagonists for treating autism spectrum disorder Download PDFInfo
- Publication number
- CA3141694A1 CA3141694A1 CA3141694A CA3141694A CA3141694A1 CA 3141694 A1 CA3141694 A1 CA 3141694A1 CA 3141694 A CA3141694 A CA 3141694A CA 3141694 A CA3141694 A CA 3141694A CA 3141694 A1 CA3141694 A1 CA 3141694A1
- Authority
- CA
- Canada
- Prior art keywords
- asd
- compound
- treatment
- pharmaceutically acceptable
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
- A61J3/074—Filling capsules; Related operations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1900190 | 2019-05-31 | ||
| HUP1900190A HU231525B1 (hu) | 2019-05-31 | 2019-05-31 | Szelektív hisztamin H3 receptor antagonisták autizmus spektrum betegség kezelésére |
| PCT/IB2020/055104 WO2020240489A1 (en) | 2019-05-31 | 2020-05-29 | Selective histamine h3 receptor antagonists for treating autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3141694A1 true CA3141694A1 (en) | 2020-12-03 |
Family
ID=89992916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3141694A Pending CA3141694A1 (en) | 2019-05-31 | 2020-05-29 | Selective histamine h3 receptor antagonists for treating autism spectrum disorder |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220235034A1 (https=) |
| EP (1) | EP3976035A1 (https=) |
| JP (1) | JP2022534973A (https=) |
| CN (1) | CN113905736A (https=) |
| CA (1) | CA3141694A1 (https=) |
| EA (1) | EA202193155A1 (https=) |
| HU (1) | HU231525B1 (https=) |
| WO (1) | WO2020240489A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE354568T1 (de) * | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
-
2019
- 2019-05-31 HU HUP1900190A patent/HU231525B1/hu unknown
-
2020
- 2020-05-29 WO PCT/IB2020/055104 patent/WO2020240489A1/en not_active Ceased
- 2020-05-29 CN CN202080040238.0A patent/CN113905736A/zh active Pending
- 2020-05-29 CA CA3141694A patent/CA3141694A1/en active Pending
- 2020-05-29 EP EP20730490.8A patent/EP3976035A1/en not_active Withdrawn
- 2020-05-29 EA EA202193155A patent/EA202193155A1/ru unknown
- 2020-05-29 JP JP2021570821A patent/JP2022534973A/ja active Pending
- 2020-05-29 US US17/614,412 patent/US20220235034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HU231525B1 (hu) | 2024-08-28 |
| US20220235034A1 (en) | 2022-07-28 |
| EA202193155A1 (ru) | 2022-03-22 |
| JP2022534973A (ja) | 2022-08-04 |
| WO2020240489A1 (en) | 2020-12-03 |
| CN113905736A (zh) | 2022-01-07 |
| EP3976035A1 (en) | 2022-04-06 |
| HUP1900190A1 (hu) | 2020-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108420819A (zh) | 用于治疗神经障碍的新组合物 | |
| MX2013010043A (es) | Terapia para transtornos neurologicos a base de baclofeno y acampros ato. | |
| AU2025279746A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| CN107567444A (zh) | 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物 | |
| CA2734859A1 (en) | Methods for treating cns disorders | |
| US20230181572A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| WO2017197177A1 (en) | Compounds to promote normal processing of app | |
| US9403755B2 (en) | Isometheptene isomer | |
| EP4251148A1 (en) | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder | |
| US20220235034A1 (en) | Selective histamine h3 receptor antagonists for treating autism spectrum disorder | |
| EA046455B1 (ru) | Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра | |
| HK40067131B (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| HK40067131A (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| EA048505B1 (ru) | Производные карбамоилциклогексана для лечения расстройства аутистического спектра | |
| OA20885A (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder. | |
| WO2020027344A1 (en) | Ch24h inhibitors for mdd use | |
| WO2002051416A1 (fr) | Medicaments ameliorant les comportements de la vie courante chez des personnes atteintes de la maladie d'alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED Effective date: 20250609 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251114 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260114 |